A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption.

The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Medullary Thyroid Cancer Adenocarcinoma Carcinoma Carcinoma, Medullary Carcinoma, Neuroendocrine Neoplasms Neoplasms by Histologic Type Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Confirmed diagnosis of medullary thyroid cancer
Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
No serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Exclusion criteria

Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
Any serious and/or unstable pre-existing medical disorders
Patients who are currently receiving any other investigational drug.

Treatment and study plan

Primary outcomes

Number of medullary thyroid cancer patients who decide to enroll in a clinical trial

Time frame: 3 months
Rate of medullary thyroid cancer patients who remain in clinical trial to trial completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

(415) 900-4227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Oct 12, 2023
Registry last updated: Oct 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting